Patent Issued in Russia, Europe, the U.S. and Japan
Paris, September 23, 2011 – Magnisense, a developer of next generation bioassays for human and animal diagnostics, food safety and environmental protection, today announced that it received notification that its Russian Patent No. 20000105511, originally issued in Russia in 2001, covering fundamental aspects of Magnisense’s MIAtek® technology, has been issued in Japan (Japanese Patent No. 565986). In addition to Russia, this patent was previously issued in other areas of the world, including the U.S. and Europe.
The patent, entitled “Method for Analyzing a Mixture of Biological and/or Chemical Components using Magnetic Particles and Device for the Implementation of said Method”, was first issued in Russia in 2001, then in Europe in 2009 and in the U.S. in 2010 and finally in Japan in August 2011. It will expire in 2021 in Europe and in 2027 in the U.S. The patented method is the essence of the company's MIAtek® technology, which enables the detection and accurate quantification of biological targets by leveraging the non-linear magnetization properties of superparamagnetic particles.
This patent is an essential piece of Magnisense's intellectual property and constitutes the cornerstone of a strong portfolio of 5 patent families that have been strengthened by the granting in Japan, a country recognized for its very rigorous patent system.
“We are very pleased with the issuance of our cornerstone patent in Japan, which reinforces our intellectual property protection in the world and provides Magnisense and its partners market exclusivity in the designated countries into 2027,” commented Jean-Patrick Voisin, Chairman and CEO of Magnisense. “With this allowance by the Japanese Patent Office coupled with our broad protection, MIAtek® technology has the potential to become the standard of point-of care testingin detecting and quantifying biological targets in whole blood, no sample preparation and therefore actual short time to result.”
About Magnisense : www.magnisense.com
Magnisense was incorporated in 2004 and has been based in Paris and San Francisco since 2007 and 2009, respectively. The company develops and markets next-generation magnetic bioassays which improve rapid diagnostic performance for human and animal diagnostics, food safety and environmental protection testing. The assays are based on a technological breakthrough: the use of magnetic beads as markers. The magnetic signal is not perturbed by the surrounding environment, which enables more sensitive, reproducible detection than can be achieved with conventional enzymatic or fluorescent labels. The Magnisense technologies enable the detection and accurate quantification of one or more biological targets in large sample volumes. Magnisense is developing two rapid test formats with a single dose, producing objective, quantifiable and traceable results via a portable reader, for different application areas:
Press and Analysts Contacts : + 1 408 666 76 39 hayat.el-yousfi@magnisense.com |